Development of Targeted Antibody Therapy to Reduce Antimicrobial Resistance-Related Morbidity and Mortality in the Erasmus Medical Centre

Development of Targeted Antibody Therapy to Reduce Antimicrobial Resistance-Related Morbidity and Mortality in the Erasmus Medical Centre - TARAME

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44672

Enrollment

Registered

2014-11-11

Start date

2015-10-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood poisoning

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Aged between 18- years and 65 years Diagnosed with sepsis and with a positive blood culture for E. coli or P. aeruginosa Signed informed consent by the patient or his/her legal representative

Exclusion criteria

Exclusion criteria: Age younger than 18 years Age older than 65 years Receiving immunosuppressive medication, including chemotherapy HIV seropositivity Hematological malignancies

Design outcomes

Primary

Measure	Time frame
The primary objective of the study is the cloning of recombinant antibodies against E. coli and P. aeruginosa to develop antibody therapy for patients suffering from nosocomial infections, including patients that are immunocompromised and have a reduced cellular immune response.	—

Secondary

Measure	Time frame
To obtain new insights into the nature of the immune response to E. coli and P. aeruginosa infections.	—

Countries

Netherlands

Outcome results